technology
Mammalian Display
Mammalian Display | FairJourney Biologics
FJB Mammalian Display: A Clinically Validated Technology Accelerating Therapeutic Antibody Development
Discover therapeutic antibodies with superior developability using FairJourney Biologics' proprietary Mammalian Display platform. De-risk your pipeline and accelerate drug development.
About the technology
FairJourney Biologics' Mammalian Display is a proprietary, clinically validated antibody engineering platform at the forefront of therapeutic antibody discovery. Designed to address critical developability issues early in the discovery process, our platform ensures the generation of abundant, high-quality antibody leads with optimal biophysical properties. This innovative approach significantly increases the likelihood of successful progression through the development pipeline, ultimately accelerating your path to the clinic. Our expertise in antibody engineering using Mammalian Display technology ensures robust and reliable outcomes.
How Our Mammalian Display Platform Works:
Our advanced Mammalian Display platform leverages cutting-edge gene editing technology to efficiently direct site-specific integration of antibody genes to create stable mammalian cell lines displaying human antibodies on their surface. Through multi-parametric FACS™ selections, we can identify the best molecules with desired target specificity and excellent developability attributes from tens of millions of antibodies in their final therapeutic format early during the selection process. IgG, VHH, bispecifics, CAR-T, and TCR candidates can be assessed directly in final format during the discovery phase.
Find our landmark platform paper here: Full article: A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing
Find our Mammalian Display Platform intellectual property here.
Find our Mammalian Display Developability intellectual property here.
A key differentiator of our system is the unique correlation between the antibody display level on in our proprietary mammalian display system and its biophysical properties in solution, directly predicting late-stage developability and performance in CMC. This allows us to select for antibodies with reduced aggregation propensity and polyspecificity, and improved colloidal stability, while critically retaining target binding, ensuring only the most favorable clones advance. This is Mammalian display for improved antibody developability in action.
Find our landmark developability paper here: Full article: Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries
Find our Mammalian Display Platform intellectual property here.
Find our Mammalian Display Developability intellectual property here.
Get to know
Key Advantages: Why Choose FJB's Mammalian Display?
Our platform is uniquely designed to address developability issues at the earliest stages of antibody discovery, mitigating costly late-stage failures. Higher display levels directly correlate with better developability, providing a built-in quality control. This is key to de-risking antibody development with mammalian display especially where sub-cutaneious administration is preferred.
As a proprietary, clinically validated antibody platform, our Mammalian Display has contributed to the discovery of multiple antibodies that have successfully entered clinical trialsfaster than the industry average, demonstrating its proven ability to deliver developable leads and accelerate late-stage development.
Utilizing advanced FACS selection, we perform high-throughput mammalian display screening of large library sizes simultaneously for target binding and developability with exceptional efficiency and predictability maximising the quality of outputs.
Antibodies are selected and displayed as full IgG, eliminating the need for reformatting and streamlining downstream development. The platform is also amenable to other formats, including VHH, VHH-Fc, bispecifics, multispecifics, antibody fusions, CAR, and TCR.
Selection in mammalian cell lines ensures antibodies undergo natural post-translational modifications, crucial for optimal function and developability.
Our strategies allow for the selection of antibodies with broad epitope specificity and high affinity, tailored to your target.
Our Mammalian Display seamlessly integrates with FJB's comprehensive antibody engineering, functional analysis, and biophysical characterization services, providing an end-to-end solution for your project. For comparative insights, we also offer Phage Display for diverse discovery needs.
Licensing Opportunity For Your Project’s Success
Interested in internalizing our cutting-edge Proprietary Mammalian Display Technology? We offer flexible Mammalian Display licensing opportunity to empower your in-house therapeutic antibody discovery and engineering efforts. This will ultimately mitigate the risk of clinical failure and speed your pipeline to the market. Our technology transfer includes comprehensive support to ensure effective integration and operation within your workflows. We also welcome collaborative developments to address your specific needs. Contact us to discuss a licensing opportunity tailored for your organization.
Ready to accelerate your therapeutic antibody developability with superior results?
Contact our experts today to discuss how our Mammalian Display platform can benefit your next project.
